These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36381682)

  • 1. The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories.
    Jalink M; Langley JM
    Paediatr Child Health; 2021; 26(2):e115-e120. PubMed ID: 36381682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.
    Bellavance M; Rohlicek CV; Bigras JL; Côté JM; Paquet M; Lebel MH; Mackie AS
    Paediatr Child Health; 2006 Jan; 11(1):19-23. PubMed ID: 19030237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab in the prevention of respiratory syncytial virus disease.
    Krilov LR
    Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007743. PubMed ID: 22336832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
    Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha I; McKoy N
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
    Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.